Dec 19 (Reuters) – MiniMed Group, the diabetes business of medical device maker Medtronic, filed for an initial public offering in the United States on Friday.
With capital markets set for the year-end holidays slowdown, corporate issuers are laying the groundwork for a potential roadshow launch in early 2026 when the IPO market kicks back into action.
Fuel distributor ARKO Petroleum and drug developer Aktis Oncology also publicly filed paperwork for a New York IPO on Friday.
MiniMed will list on the Nasdaq under the symbol “MMED”. Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are the lead underwriters for the IPO.
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shinjini Ganguli)
